Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments
REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer Cell Death
Save time and jump to the most important pieces.
Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy
License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas, Nov. 20, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University's patent rights relating toits lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of
REQORSA Modulates In Vivo Immune Responses Against Cancers AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-1
AUSTIN, Texas, Oct. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its participation in the upcoming BIO Europe Conference, taking place Nov. 4-6, 2024 in Stockholm, Sweden and taking place virtually Nov. 12-13, 2024. Attending in-person will be Genprex's Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, Esq. In addition, the Company's President and Chief Executive Officer,
National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00
8-K - Genprex, Inc. (0001595248) (Filer)
8-K - Genprex, Inc. (0001595248) (Filer)
10-Q - Genprex, Inc. (0001595248) (Filer)
4 - Genprex, Inc. (0001595248) (Issuer)
4 - Genprex, Inc. (0001595248) (Issuer)
4 - Genprex, Inc. (0001595248) (Issuer)
SC 13G/A - Genprex, Inc. (0001595248) (Subject)
SC 13G - Genprex, Inc. (0001595248) (Subject)
SC 13G - Genprex, Inc. (0001595248) (Subject)
https://www.genprex.com/downloads/2024-genprex-stockholder-letter.pdf
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million. Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million. Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million. Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million. Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million. Purple Biotech (NASDAQ:PPBT) shares moved upwards b
HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.